Literature DB >> 17366055

Liver biopsy performance and histological findings among patients with chronic viral hepatitis: a Danish database study.

Peer Brehm Christensen1, Henrik Bygum Krarup, Axel Møller, Alex Lund Laursen, Mette S Kjaer, Marianne Orholm, Jens Lindberg, Karin Groenbaek, Hans Kromann-Andersen, Nina Weis.   

Abstract

We investigated the variance of liver biopsy frequency and histological findings among patients with chronic viral hepatitis attending 10 medical centres in Denmark. Patients who tested positive for HBsAg or HCV- RNA were retrieved from a national clinical database (DANHEP) and demographic data, laboratory analyses and liver biopsy results were collected. A total of 1586 patients were identified of whom 69.7% had hepatitis C, 28.9% hepatitis B, and 1.5% were coinfected. In total, 771 (48.6%) had a biopsy performed (range 33.3-78.7%). According to the Metavir classification, 29.3% had septal fibrosis (> or =F2) and 13.9% had cirrhosis (F4). The frequency of cirrhosis varied from 8.3 to 18.6% among centres, and was independently associated with age, male gender, elevated alanine-aminotransferase (ALT) and non-Danish origin. Among 141 patients with hepatitis C and known duration of infection, cirrhosis had developed in 23% after 20 y of infection. Age above 40 y was a better predictor of cirrhosis than elevated ALT. National database comparison may identify factors of importance for improved management of patients with chronic viral hepatitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17366055     DOI: 10.1080/00365540600978864

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  3 in total

1.  Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.

Authors:  John C Hoefs; Mitchell L Shiffman; Zachary D Goodman; David E Kleiner; Jules L Dienstag; Anne M Stoddard
Journal:  Gastroenterology       Date:  2011-06-12       Impact factor: 22.682

2.  Microfibrillar-Associated Protein 4: A Potential Biomarker for Screening for Liver Fibrosis in a Mixed Patient Cohort.

Authors:  Susanne Gjørup Sækmose; Belinda Mössner; Peer Brehm Christensen; Kristoffer Lindvig; Anders Schlosser; René Holst; Torben Barington; Uffe Holmskov; Grith Lykke Sorensen
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

3.  Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.

Authors:  Jannie Pedersen; Tanja B Jensen; Thomas H R Carlsen; Kristian Schønning; Peer Brehm Christensen; Alex Lund Laursen; Henrik Krarup; Jens Bukh; Nina Weis
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.